The modern era of treatment for acute myelogenous leukemia (AML) began with the introduction of anthracyclines and cytosine arabinoside as critical components providing synergistic activity in induction therapy for patients with AML. During the early years, a debate ensued regarding the issue of whether such induction therapy should be offered to older adults, in preference to supportive care only. And if given, whether it should be administered immediately at diagnosis or whether a limited observation period -until clinical progression is appropriate. Finally, there is always the question of whether it is critical that complete remission (CR) be achieved with the initial induction therapy.
There are very few studies that have prospectively evaluated the need for standard induction therapy in older patients with AML. There is only one such older study, 1 which prospectively compared patients over 65 years, giving them standard induction therapy vs low-dose cytarabine. The result was a statistically significant improvement in the CR rate, although not in the overall survival. An older study from the European Organization for Research and Treatment of Cancer Leukemia Group (EORTC) 2 randomized patients at diagnosis to either receive standard therapy or wait until disease progression. This small study also reported a major difference in the CR rate in favor of those patients treated immediately at diagnosis. Figure 1 reports on data from a recent study of the Eastern Cooperative Oncology Group (ECOG) for older adults 3 and compares the overall survival of patients who reached CR after standard induction therapy vs those who did not reach CR with the initial induction therapy on study, although they may have reached this with subsequent therapy. The 5-year survival for this latter group is only 2.5% compared with 14%. Thus, it would seem that for any chance of meaningful long-term survival, it is indeed critical to achieve CR with induction therapy.
Conventional wisdom and a multitude of uncontrolled data have established the role for induction therapy for AML in older adults, based mostly on the fact that modern studies have reported that between 40 and 50% of older adults can achieve a CR with standard induction therapy ( Table 1 ). This of course refers only to older adults who are selected upfront and deemed fit to undergo such therapy.
Of greater interest lately is the issue regarding the role for postremission therapy in older adults. There has never been a formal study addressing this in older AML patients, in a manner similar to a study in younger adults two decades ago. 4 In that study, in patients under 55 years, patients were assigned, as postremission therapy, to receive an allogeneic bone marrow transplant if they had an HLA-matched family donor. If no donor was available, they were randomized between intensive consolidation with cytarabine, lower doses of maintenance therapy or observation alone. The observation arm was terminated early by the National Cancer Institute (NCI) in the US as all patients who had not received any form of postremission therapy relapsed early and there was even a significant advantage for patients who had only received maintenance therapy. However, although the need for postremission therapy has been unequivocally established for younger adults, the issue is still open for older adults as it has never been unequivocally demonstrated that offering any form of postremission therapy affects ultimate long-term survival. 5 The prognosis for older patients with AML is compounded by two important factors. First, this group has biologic features that predict for a poor outcome. 6 These include a high portion of patients with intermediate and unfavorable cytogenetics; a high incidence of antecedent hematologic disorders such as myelodysplasia; a high frequency of leukemic cells that express the multidrug resistance gene (MDR-1); a high incidence of trilineage dysplasia and an increased incidence of Flt3 internal tandem duplication, the most frequent gene mutation in AML. 7 Second, and perhaps more important, is the fact that the most intensive regimens for older adults are far less intense than would be considered optimal therapy for even the most favorable subtypes of AML in younger adults and, therefore, the question that troubles most investigators is whether it is appropriate to administer maximally tolerated postremission therapy, or, indeed, whether any postremission therapy is necessary in this group of patients. The problem with older patients is not one of achieving an initial response. It is the fact that no matter what one does, very few of them remain in remission and very few survive (Figure 2 ). This is somewhat analogous to the situation with Philadelphia chromosomepositive acute lymphocytic leukemia (ALL) patients who are not transplanted in first remission.
Major cooperative groups over the past decade have evaluated the role of intensifying consolidation therapies and several important issues may be learned. The Medical Research Council (MRC) in Britain published the largest study of older patients with AML. 8 This study compared older adults who achieved CR and received one course of consolidation following which they were randomized to three further cycles vs observation only. The data demonstrated quite clearly that in the dose that was given in this study there was no particular value to further intensification after a single course of consolidation therapy. The German AML Cooperative Group 9 randomized older patients who went into CR and received one course of consolidation to either one course of very intensive consolidation or maintenance therapy, for 3 years. The reported data showed that maintenance therapy was clearly superior to a second intensive course of consolidation. A study by the Cancer and Leukemia Group B (CALGB) 10 compared two cycles of a somewhat novel regimen of intensive cytarabine and mitoxantrone vs four cycles of lower doses of cytarabine given for 5 days. Once again, this study demonstrated no benefit for the more intensive postremission regimens. Figure 3 shows the data on the postremission therapy from a study from an ECOG study 11 that now has a 7-year follow-up. There is no postremission randomization and all received just a single course of high-dose cytarabine. The disease-free survival at 5 years is 20% after only a single course of consolidation. Thus, although not all study arms are strictly comparable, as intensity is sometimes compared with less intense arms given for a longer duration, the preponderance of the data from previous trials suggests that within the constraints of total therapy that can be tolerated in this age group there is little evidence to justify administration of maximally tolerated consolidation. This leads us to the question of what the current approaches are and where progress is likely to be made? Table 2 illustrates a selection of some of the major approaches that are currently ongoing for postremission therapy. The CALGB focuses on giving two courses of high-dose cytarabine and evaluating the role of genasense, which is an antisense oligonucleotide that downregulates bcl2. This is based on data that have demonstrated that this is feasible without added toxicity. 12 It is, however, not clear from what has been learned from previous studies that there is in fact a benefit for giving two courses of high-dose cytarabine consolidation.
The current ECOG study evaluates the role of zosuquidar, which is a very potent MDR modulator. 13 In this study, patients receive two cycles of postremission therapy and in the second cycle patients receive either zosuquidar or placebo. Again, one can argue with the rationale for administering two cycles of postremission therapy here.
The MRC in Britain (AML14) has been conducting one of the most interesting studies, which actually attempts, prospectively, to answer the key question of whether intensive postremission therapy is better than nonintensive therapy. Among several treatment options, there is also a nonintensive arm where patients receive only hydroxyurea or low-dose cytarabine with or without gemtuzumab ozogamicin. The intensive vs nonintensive randomization is offered in the instances where the physician and/or patient are not sure whether they wish to undergo intensive therapy and actually agree to be randomized. In essence, this is a study that everyone wanted to see. However, the number of patients randomized to the nonintensive arm is minimal and it is likely that such a trial probably cannot be conducted and we may never get an unequivocal answer. The current German AML Cooperative Group study does not have a postremission randomization, but offers patients a single course of postremission consolidation followed by 3 years of maintenance. One of the most interesting studies is the one conducted by the Southwest Oncology Group (SWOG). This study (S0125) fundamentally evaluates prospectively the role of reduced intensity allogeneic transplantation in an attempt to harness the immunologic effects of graft-versus-leukemia in an older population. Thus, patients who do not have an HLAmatched sibling receive two identical courses of consolidation with cyclosporine A, again, without data that two are better than one (S0301). However, patients who do have an HLA-matched sibling are offered a reduced-intensity allogeneic BMT. This study should be of fundamental importance as the performance of reduced-intensity allogeneic transplants has been conducted Outcome of AML by age. in many centers in a mostly uncontrolled manner and it is difficult to interpret the results in select groups of patients. This study attempts, almost for the first time, to evaluate this in a prospective fashion and compare it with a concurrent control group that will not receive an allogeneic transplant. The major advantage of this form of therapy is the fact that this offers the potential for curative therapy in older adults without the use of intensive myeloablative therapy that such patients may not be able to tolerate. One important exception to this group of patients are the older adults that present with favorable cytogenetics. The incidence of patients with favorable cytogenetics actually increases with age, 14 although this represents a small minority of the total number of older patients with AML -mostly due to the far greater increase in the incidence of patients with intermediate and unfavorable cytogenetics. The data suggest that such patients have a better prognosis also in older adults and have a 20-30% chance of long-term survival. 15 In such patients it must be assumed -although this has never been proven -that they should be offered for postremission as intensive therapy as they are able to tolerate. Conversely, the data suggest that patients who have unfavorable cytogenetics have a 5-year survival of only about 2.5% and a cogent argument for offering such patients experimental therapy or only palliative care as postremission therapy is often made (Table 3) .
In summary, it seems that much remains uncertain regarding the need for and the best postremission therapy in older adults. It was also not clear that we have learned the most appropriate lessons from data that have been published over the past decade. The next decade should help verify whether reducedintensity allogeneic transplants can make a major impact on the long-term outcome for older patients with AML and, hopefully, should establish the role of some of the newer biologic response modifiers. Data have demonstrated that gemtuzumab ozogamicin 16 and the farnesyltransferase inhibitors 17 are active as single agents in AML, and current trials are under way to establish their role in the postremission therapy of older adults. Other potential agents, such as antiangiogenic agents, Flt3 tyrosine-kinase inhibitors, 18 histone deacetylase inhibitors 19 and the apoptosis inhibitors 20, 21 are at a relatively preliminary stage of study. Perhaps somewhat surprisingly, recent studies suggested that the addition of all-trans-retinoic acid (ATRA) as postremission therapy may improve long-term survival. 22 Despite a compelling biologic rationale, early clinical experience does not lead one to predict that any of these newer targeted agents will significantly alter the outcome for older patients with AML, in a manner similar to ATRA in APL or imatinib mesylate in CML. 
